Skip to main
TEM

TEM Stock Forecast & Price Target

TEM Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 28%
Hold 33%
Sell 6%
Strong Sell 0%

Bulls say

Tempus AI is positioned for strong growth in the biopharma sequencing and diagnostics markets, with a diverse and impressive product portfolio and a highly scalable AI platform. Its recent FDA clearance for Tempus ECG-PH expands its addressable market and reinforces the potential for its ECG-AI platform. With a strong track record in precision medicine diagnostics and a partnership with Merck and Moderna, Tempus AI is poised for significant revenue growth and potential partnerships with other biopharma companies. Although there are some risks to achievement of its $73 price target, the company remains a top performer in the healthcare technology space and is well-positioned for success in the future.

Bears say

Tempus AI is facing significant risks in the near future due to its high dependency on Medicare coverage and partnerships with other companies for its AI-driven diagnostic and testing platforms. Its recent acquisition of Personalis may add value, but full commercialization has yet to be achieved. Additionally, the lack of formal CDx designation for Intismeran may hinder its revenue potential, making it difficult for Tempus AI to achieve sustainable profitability.

TEM has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 28% recommend Buy, 33% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tempus AI Inc (TEM) Forecast

Analysts have given TEM a Buy based on their latest research and market trends.

According to 18 analysts, TEM has a Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tempus AI Inc (TEM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.